Atlas Trials

A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Clinical trial NCT07435311 · COMPLETED

Trial details

NCT number
NCT07435311
Sponsor
R-Pharm
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Head and Neck Squamous Cell Carcinoma
Start date
2020-06-15
Primary completion
2024-07-17
Enrollment
118

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.